INAB Stock — IN8bio Inc.: Cash, EV, Pipeline

Share price

$1.08

Market cap

$10.6M

Cash

$18.1M

Enterprise value

-$7.5M

Balance sheet

Cash	$18.1M
Debt	$0.0M
Net cash	$18.1M
Enterprise value	-$7.5M
Basic shares	9.9M shares
Fully diluted shares	24.5M shares
Fully diluted market cap	$26.5M
Cash per share	$1.83

Cash figures as of 2026-06-30. Database snapshot: 2026-09-21.

Price history

Loading INAB daily closes…

Loading price history…

Pipeline assets

INB-100

Phase 1 · Active Modality: cell therapy (allogeneic donor-derived expanded and activated gamma-delta T cells, DeltEx)

Indications

Acute myeloid leukemia / high-risk leukemias undergoing haploidentical HSCT (Phase 1)

Catalysts

— late 2026

Status note Lead program. Investigator-sponsored Phase 1 completed primary enrollment; RP2D determined; expansion cohort at RP2D enrolling (target up to 15 additional patients, minimum 25 total).

INB-200

Phase 1 · Active Modality: cell therapy (drug-resistant immunotherapy, DeltEx DRI gamma-delta T cells engineered with MGMT-expressing lentivector)

Indications

Newly diagnosed glioblastoma (GBM) (Phase 1)

Status note Investigator-sponsored Phase 1 (NCT04165941) dosing completed; patients followed for PFS/OS. Peer-reviewed Phase 1 data published in JCO July 2026.

INB-400

Phase 2 · Active Modality: cell therapy (drug-resistant immunotherapy, DeltEx DRI gamma-delta T cells)

Indications

Newly diagnosed glioblastoma (GBM) (Phase 2)

Catalysts

— late 2026

Status note Phase 2 enrollment suspended September 2024 following pipeline review to conserve capital; treatment of enrolled patients completed, IND remains open (10-K). DeltEx DRI gamma-delta T cells in newly diagnosed GBM.

INB-619

Preclinical · Active Modality: T cell engager (gamma-delta TCE, INB-600 platform)

Target CD19

Indications

B-cell-driven autoimmune diseases (e.g. systemic lupus erythematosus) (Preclinical)

Catalysts

— 2H 2026

Status note Proprietary internally developed INB-600 TCE platform candidate; deep B-cell depletion via selective gamma-delta T cell activation/expansion shown (ACR Convergence 2025).

INB-300

Preclinical · Active Modality: cell therapy (targeted non-signaling gamma-delta T cell based CAR construct, nsCAR)

Target CD33/CD123

Status note Preclinical program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.

INB-500

Preclinical · Active Modality: cell therapy (gamma-delta T cells from iPSCs)

Status note Preclinical iPSC gamma-delta T cell program suspended in development due to pipeline prioritization and market conditions; not formally discontinued.

Per-asset detail extracted from the 10-Q filed 2026-08-06. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.

Pipeline

Lead drug	Autologous genetically modified gamma-delta T cells
Lead indication	Glioblastoma
Lead phase	Phase 2
Active trials	1
Collaborator trials	1

Active clinical trials

Trial	Phase	Status	Role	Sponsor	BP	Condition(s)	Mgmt guide
NCT05664243	Phase 2	Active, not recruiting	Sponsor	INAB	—	Glioblastoma	—
NCT03533816	Phase 1	Recruiting	Collaborator	University of Kansas Medical Center	—	Acute Myeloid Leukemia; Chronic Myeloid Leukemia; Acute Lymphoblastic Leukemia	—

Sponsor-matched active trials from ClinicalTrials.gov (1 as sponsor, 1 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.

View all 2 active trials for In8bio Inc. on ClinicalTrials.gov

No specialist-fund holders in 13F data for this company.

INAB — IN8bio Inc.

Balance sheet

Price history

Pipeline assets

Pipeline

Active clinical trials